Aesir Health


Aesir Health was established in 2004 in Melbourne and has supported clinical education and patient support programs nationally for nearly 20 years. The majority of our staff are highly qualified health care professionals and medical scientists. We have designed, built, managed and published programs in many different therapeutic areas including diabetes, rheumatology, gastroenterology, dermatology, prostate cancer, ophthalmology, cardiovascular disease, hepatology to name a few.


Our philosophy is simple.
Focus on the Patient, Focus on the Medicine.
To us, this is fundamental to whatever we do. If our programs address true clinical need and add real value to the patient, then our focus is sound.

Our Expertise

Driving healthcare forward

Aesir Health is a leading and award winning provider of medical education and patient support in Australia. We are a highly specialised group that provides bespoke programs delivered by teams of healthcare professionals on behalf of the pharmaceutical, medical device and healthcare industries.

Management & Staff

The management team at Aesir Health have over 100 years of combined experience in the pharmaceutical industry, clinical education and PSPs. All programs are built in consultation with key internal and external stakeholders to ensure that the service to patients is meeting their clinical need.
The staff are healthcare professionals & medical scientists with colleagues in IT, finance, logistics and operations. Head office is in Melbourne with nurses in most capital cities

Our Directors

Dr Sherif Youssef

We are Award winning industry leaders

Aesir Health has been the recipient of 3 PRIME (Pharmaceutical Research, Innovation, Marketing Excellence) for Innovation (twice) and Customer Excellence. Our programs, models of care and patient outcomes have been published several times at Australian conferences as well as in peer reviewed publications.
Innovation and Excellence in Patient Support Awards


Aesir Health programs often have a unique view of patients with these complex conditions and the use of highly specialised products as our programs are national and often well subscribed. This affords us the opportunity to collate data, de-identify and then publish our observations as real-world evidence, especially in the impact of these Patient Support Programs (PSPs). Some of the recent publications are listed below. For our full list, please contact us.

ASCIA 2022

ANZAN 2022

ASCIA 2021

Dr David Tognarini

David has a B.Sc (Hons) in Pharmacology and PhD in Medicine from the University of Melbourne under the guidance of Prof Rob Moulds (AO). He subsequently moved in a career within the pharmaceutical industry with GlaxSmithKline (Melbourne, Australia) as a medical product specialist in therapeutic areas such as gastroenterology, hepatology & infectious diseases before relocating to the GSK UK as an international Product manager within R&D for hepatology and respiratory.
David returned to Australia in 2004 & established Aesir Health, a small dedicated company focused on supporting complex medications and providing services to the pharmaceutical industry. Aesir was initially a consultancy which, under the guidance of David and Sherif Youssef (PhD) grew to a become one of Australia’s leading providers of patient support programs (PSPs) winning awards for Innovation and Customer excellence. The philosophy has always been and remains to this day, “Focus on the Patient, focus on the Medicine” so all programs are built to meet the clinical and patient need in partnership with the referring clinician.
David & Sherif established Cortex Health in 2013 with the same desire and intent to support Australians with rare conditions as a product distributer. In partnership with Cambrooke Therapeutics, Cortex introduced glycomacropeptide (GMP) into Australia for those with PKU which was innovative and bold at the time. This subsequently changed the entire treatment paradigm for PKU & tyrosinaemia by offering a significantly different and advanced formula. Cortex has expanded further to introduce advanced formula for ketogenic diet therapy in intractable epilepsy, severe protein allergy & very recently into medical devices for bone mineral density / osteoporosis diagnosis & medical creams for eczema and psoriasis.